½ÃÀ庸°í¼­
»óǰÄÚµå
1631190

ÀúºÐÀÚ API ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, Á¦Á¶¾÷üº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Small Molecule API Market Size, Share & Trends Analysis Report By Type (Synthetic, Biotech), By Manufacturer, By Application (Oncology, Pulmonology, CNS, Endocrinology), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀúºÐÀÚ API ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ÀúºÐÀÚ API ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2,970¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â CAGRÀº 5.6%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°è ÀǾàǰ ¼ö¿ä Áõ°¡¿Í ÀúºÐÀÚ ±â¹Ý ½Å¾àÀÇ ³ôÀº ½ÂÀηüÀÌ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå¿¡ ÁøÀÔÇÏ´Â ½Å¾àÀÇ Áõ°¡´Â ÁÖ¿ä ÁøÀÔ ±â¾÷µé¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â NCBI¿¡ µû¸£¸é FDA°¡ ½ÂÀÎÇÑ ÀǾàǰÀÇ 75%´Â ÀúºÐÀÚ ÀǾàǰÀ̾ú°í, Ä¡·á ºÐ¾ß´Â ¾Ï ºÐ¾ß°¡ Áö¹èÀûÀ̾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÂÀÎ Áß 50% ÀÌ»óÀÌ CDMOÀÇ ¼ºÀå·üÀ» ³ôÀÌ´Â Á¦Ç° »ó¿ëÈ­¸¦ À§ÇØ CDMOÀÇ Áö¿øÀ» ÇÊ¿ä·Î ÇÏ´Â Áß¼Ò±â¾÷¿¡ ÀÇÇÑ ½ÂÀÎÀ̾ú½À´Ï´Ù.

COVID-19 »çÅ·ΠÀÎÇØ ÀúºÐÀÚ ¿ø·áÀǾàǰ ºñÁî´Ï½ºÀÇ °ø±Þ¸Á ´ÜÁ¡ÀÌ µå·¯³µ½À´Ï´Ù. ÀÌ¿¡ µû¶ó, °í°´µéÀ» À§ÇÑ ¿£µå Åõ ¿£µå ÅëÇÕ °ø±Þ¸ÁÀ» ±¸ÃàÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°Ô µÇ¾ú°í, À̸¦ À§ÇÑ Á¤ºÎÀÇ Áö¿øÀÌ °­È­µÇ¸é¼­ À¯·´°ú ¹Ì±¹ ³» ½Ã¼³ ¼ö°¡ Áõ°¡Çß½À´Ï´Ù.

¼¼°è ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ °¢ ȸ»ç´Â Àμö ÇÕº´À» ÀÚÁÖ ½Ç½ÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù Novasep°ú PharmaZellÀº º¹ÀâÇÑ ÀúºÐÀÚ È­ÇÕ¹° ¹× Ư¼ö ¿ø·áÀǾàǰ Á¦Á¶¸¦ À§ÇÑ ±â¼ú ÁÖµµÇü CDMO ¼³¸³À» ¸ñÇ¥·Î ÇÏ´Â Àü·«Àû ÇÕº´À» ¹ßÇ¥Çß½À´Ï´Ù.

½ÃÀå È®´ë¿Í ´Ù°¢È­´Â ½ÃÀå Á¡À¯À²À» À¯ÁöÇϱâ À§ÇØ ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚµéÀÌ »ç¿ëÇÏ´Â Áß¿äÇÑ Àü·«ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ·ÐÀÚ´Â 2021³â 4¿ù ½ºÀ§½º¿¡ ÀúºÐÀÚ È­ÇÕ¹° Á¦Á¶ ½Ã¼³À» °Ç¼³Çϱâ À§ÇØ 2¾ï 1,860¸¸ ´Þ·¯ÀÇ ÅõÀÚ °èȹÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½Ã¼³À» ÅëÇØ Á¦Ç°ÀÇ ¿¬¼Ó¼º°ú À¯¿¬ÇÑ °ø±ÞÀ» º¸ÀåÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Áß±¹, Àεµ, µ¿³²¾Æ½Ã¾Æ µî ½ÅÈï ½ÃÀåÀº Å« ¼ºÀå ±âȸÀÔ´Ï´Ù. ¶ÇÇÑ, 'ÇÒ¶ö API'¿Í °°Àº Æ´»õ ½ÃÀåÀº ÁÖ·Î Áßµ¿ ¹× µ¿³²¾Æ½Ã¾Æ ±¹°¡µéÀÇ ÀǾàǰ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Ãß°¡ÀûÀÎ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÇÕ¼º ÀúºÐÀÚ API ºÎ¹®Àº »ê¾÷ÀÇ º¯È­ÇÏ´Â ¿ä±¸»çÇ׿¡ ´ëÀÀÇÏ´Â ¼Ò±Ô¸ð ±â¾÷ ¹× CDMOÀÇ Á¸Àç¿¡ ÀÇÇØ Å©°Ô °ßÀεǰí ÀÖ½À´Ï´Ù.

ÀúºÐÀÚ API ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2024³â¿¡´Â ÇÕ¼º API°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â ´ë·®À¸·Î ÇÊ¿äÇÑ ÀǾàǰ »ý»ê¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä¿¡ ±âÀÎÇÕ´Ï´Ù.
  • Áß°ß-Áß¼Ò±â¾÷ÀÌ »ó¾÷Àû »ý»êÀ» ¾Æ¿ô¼Ò½Ì¿¡ ÀÇÁ¸Çϰí Àֱ⠶§¹®¿¡ ¾Æ¿ô¼Ò½Ì Á¦Á¶ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ¾Ï Ä¡·áÁ¦ÀÇ º¸±ÞÀÌ È®´ëµÇ°í, ¿ø¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Ȱ¹ßÇÏ°Ô Ã¢ÃâµÇ°í ÀÖ¾î ¿ëµµº°·Î´Â ¾Ï ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç¿Í ÀÌ Áö¿ªÀÇ API Á¦Á¶ ¿ª·® °­È­¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø Áõ°¡·Î ÀÎÇØ 2024³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀúºÐÀÚ API ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå ÀúºÐÀÚ API ½ÃÀå : À¯Çü ºñÁî´Ï½º ºÐ¼®

  • À¯Çü ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
  • ÇÕ¼º
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö

Á¦5Àå ÀúºÐÀÚ API ½ÃÀå : Á¦Á¶¾÷ü ºñÁî´Ï½º ºÐ¼®

  • Á¦Á¶¾÷ü ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • Á¦Á¶¾÷ü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, Á¦Á¶¾÷üº°, 2018-2030³â
  • »ç³»
  • ¾Æ¿ô¼Ò½Ì

Á¦6Àå ÀúºÐÀÚ API ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ¿ëµµ ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • ½ÉÇ÷°üÁúȯ
  • Á¾¾çÇÐ
  • ÁßÃ߽Űæ°è¿Í ½Å°æÇÐ
  • Á¤Çü¿Ü°ú
  • ³»ºÐºñÇÐ
  • È£Èí±â°ú
  • ¼ÒÈ­±â³»°ú
  • ½ÅÀåÇÐ
  • ¾È°ú
  • ±âŸ

Á¦7Àå ÀúºÐÀÚ API ½ÃÀå : À¯Çü°ú Á¦Á¶¾÷ü¿¡ ÀÇÇÑ Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
    • ±¹°¡º°, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±¹°¡º°, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • Âü¿©ÀÚ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Ç ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ °³¿ä/»óÀå ±â¾÷
    • Merck &Co., Inc
    • AbbVie, Inc.
    • Bristol-Myers Squibb Company
    • Albemarle Corporation
    • Boehringer Ingelheim International GmbH
    • Cipla, Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries Ltd.
ksm 25.03.07

Small Molecule API Market Growth & Trends:

The global small molecule API market size is expected to reach USD 297.0 billion by 2030, expanding at a CAGR of 5.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. It is driven by an increase in demand for pharmaceuticals globally and a high rate of new small molecule-based drug approval.

The increasing number of new pharmaceuticals entering the market is creating a lucrative opportunity for key players. For instance, as per NCBI in 2021, 75% of the drugs accepted by the FDA were small molecules, with the dominant therapeutic area being oncology. Over 50% of these approvals were from small and mid-sized companies which require support from CDMOs for the commercialization of products that enhance the growth rate of CDMOs.

The COVID-19 pandemic has made supply-chain shortcomings in the small-molecule API business apparent, as most of the production facilities are located in Asian nations such as India and China. This has increased the focus of players on creating an end-to-end integrated supply chain for the clients and increased the number of facilities in western countries with heightened support from the government for doing the same.

Merger and acquisition activities are frequently being undertaken by the players to meet the soaring demands globally. For instance, in April 2022, Novasep and PharmaZell announced a strategic merger for the creation of a leading technologically-driven CDMO for complex small molecules and specialty API production.

Expansion and diversification are becoming key strategies used by key players in the market to maintain their market share. For instance, in April 2021, Lonza announced its investment plan of USD 218.6 million for the construction of a manufacturing complex for small molecules in Switzerland. The facility is expected to ensure continuity and flexibility of supply for the products.

Emerging markets such as China, India, and Southeast Asia represent significant opportunities for growth. Furthermore, niche areas such as "halal API" further present growth opportunities owing to the rise in the demand for drugs in the segment, majorly in Middle Eastern and Southeast Asian nations. The synthetic small molecule API segment is largely driven by the presence of small companies and CDMOs that cater to the changing requirements of the industry.

Small Molecule API Market Report Highlights:

  • In 2024, synthetic APIs held the largest market share attributable to the high demand for the production of pharmaceuticals that are required in high volume
  • The outsourced manufacturing segment held the largest market share owing to a dependency of small and mid-sized companies on outsourcing for commercial production
  • Oncology is projected to grow at the fastest rate in the application segment as the adoption of cancer treatments is rising, creating a strong demand for API
  • North America dominated the market in 2024 due to the presence of key players and rising support from the government for enhancing the API manufacturing capacity of the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Manufacturer
    • 1.2.3. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Small Molecule API Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Small Molecule API Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 4.4. Synthetic
    • 4.4.1. Synthetic Market, 2018 - 2030 (USD Billion)
  • 4.5. Biotech
    • 4.5.1. Biotech Market, 2018 - 2030 (USD Billion)

Chapter 5. Small Molecule API Market: Manufacturer Business Analysis

  • 5.1. Manufacturer Market Share, 2024 & 2030
  • 5.2. Manufacturer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Manufacturer, 2018 to 2030 (USD Billion)
  • 5.4. In-house
    • 5.4.1. In-house Market, 2018 - 2030 (USD Billion)
  • 5.5. Outsourced
    • 5.5.1. Outsourced Market, 2018 - 2030 (USD Billion)

Chapter 6. Small Molecule API Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Billion)
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Billion)
  • 6.5. Oncology
    • 6.5.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 6.6. CNS and Neurology
    • 6.6.1. CNS and Neurology Market, 2018 - 2030 (USD Billion)
  • 6.7. Orthopedic
    • 6.7.1. Orthopedic Market, 2018 - 2030 (USD Billion)
  • 6.8. Endocrinology
    • 6.8.1. Endocrinology Market, 2018 - 2030 (USD Billion)
  • 6.9. Pulmonology
    • 6.9.1. Pulmonology Market, 2018 - 2030 (USD Billion)
  • 6.10. Gastroenterology
    • 6.10.1. Gastroenterology Market, 2018 - 2030 (USD Billion)
  • 6.11. Nephrology
    • 6.11.1. Nephrology Market, 2018 - 2030 (USD Billion)
  • 6.12. Ophthalmology
    • 6.12.1. Ophthalmology Market, 2018 - 2030 (USD Billion)
  • 6.13. Others
    • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Small Molecule API Market: Regional Estimates & Trend Analysis by Type and Manufacturer

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Small Molecule API Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Small Molecule API Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Small Molecule API Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Australia Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. South Korea Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Small Molecule API Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Small Molecule API Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Small Molecule API Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. AbbVie, Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Bristol-Myers Squibb Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Albemarle Corporation
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Boehringer Ingelheim International GmbH
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Cipla, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dr. Reddy's Laboratories Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Aurobindo Pharma
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Sun Pharmaceutical Industries Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦